Diamatrix Diagnostic tests
DiaMatrix Ltd is developing a new platform technology for “dipstick” diagnostic tests, such as pregnancy tests and illegal drug tests. The new rapid tests will simplify manufacturing, reduce costs and improve performance. The company is also developing a novel technology for biosensor fabrication.
EvanesCo Medical Sensor technology for diagnostic assays
Evanesco Medical is developing an in vitro diagnostics platform based on small sensors that provide real-time information about the composition and material properties of fluids. The technology offers key advantages of sensitivity, specificity and speed of measurement. Applications in near patient testing for infectious diseases and critical care are being developed.
Macro-Conex Clinical Chemistry
Macro-Conex has developed a cost-effective, safe, rapid and easy to use method for the linking of macro-molecules for use in the diagnostics, pharmaceutical, chemical, biotechnology and electronics industries. Macro-Conex offers an antibody-enzyme conjugate synthesis service based on a recently filed patent. A scientific and business management consultancy is also available on the development of DNA and immunoassays for infectious disease and fertility, in the areas of DNA and protein chemistry. The service is provided by Dr. Mock, who has a background in the chemical, oil, pharmaceutical and diagnostics sectors and experience in biosensors, optical fibre and laser technology.
Ocuity Ltd. Photonic component R&D
Ocuity is the world leader in reconfigurable no-glasses 2D/3D display technologies. Our patented Polarisation Activated Microlens technology is licensed to major flat-panel display manufacturers to enable high quality 3D images to be viewed on their products without glasses, and without compromising the regular 2D display performance. All this can be done by a thin optical element attached to the outside of the display and at a small premium to the base panel cost. Our technology is compatible with phone displays, laptops and desktop monitors. Applications include stereo 3D gaming, 3D-DVD and 3D picture messaging.
PepTcell Immunology
PepTcell Limited is a company with specific focus on the area of immunology. It has just completed preclinical studies for novel vaccines against Influenza and HIV. PepTcell, due to an innovative proprietary technology that enables it to determine appropriate and conserved vaccine targets, has been able to complete this work in a reduced space of time (months) and at a very low cost. PepTcell is willing to license this proprietary technology to other companies interested in vaccine or biologicals research.
ProKyma Technologies Ltd. Purification by Sonic separation
Sensitive detection methods are limited by the purity of the starting material. Techniques are available to purify and concentrate biological specimens but these methods are often labour intensive or only partly effective. Major improvements in analysing biological samples such as bacteria, cells and DNA require improved sample preparation. ProKyma’s Sonic Separation technology provides a means for concentrating and purifying cells or micro-organisms. Sonic Separation can also be used to isolate or analyse cell aggregates, for example in blood grouping and serology. ProKyma is based on Dstl's proprietary ultrasound technology for manipulating particles.
SmartSensor telemed Smartcard test devices
SmartSensor telemed is developing an award winning approach to providing healthcare management services en mass to millions of people with, or at risk from, chronic diseases. SmartSensor telemed’s innovative approach combines biosensors, electronics and IT to create a novel e-health platform technology for diagnostic screening and monitoring.
UroSens Diagnostic solutions in urinogenitary oncology
UroSens develops and commercialises point-of-care tests for cancers of the urinogenitary tract for use in the urology clinic or doctor's surgery. The initial target is bladder cancer, the fifth most common cancer in the UK with the highest recurrence rate of any malignancy. The company's key technology provides a highly sensitive and specific test, based on intellectual property exclusively licensed from Cancer Research Technology Ltd, the technology transfer arm of Cancer Research UK.
Associated Companies based at the Cherwell Innovation Centre
Hybrid Systems Ltd Gene therapy and Contract research
Hybrid Systems Ltd. is exploiting the interface between polymer chemistry and biology to generate new products and tools for applications in areas as diverse as gene therapy, vaccination, agriculture and bioremediation. The company's principal technology enables simple non-genetic coating of viruses, bacteria and spores, using hydrophilic polymers, to create safer and more versatile biological agents. The company's primary focus is currently in the area of gene therapy for cancer. The versatile polymer-coated viral and non-viral biological agents that have been generated are effective at evading immuno-detection and can be targeted to specific cells and tissues by incorporation of specific cellular receptor-binding moeties. These 'stealth' vectors should provide a safe and efficient means of directing genetic therapies to particular cell types, even when dispersed throughout the body, without affecting surrounding non-target tissues.
Everest Biotechnology Manufacture of research antibodies
Everest Biotech manufactures novel antibodies for the proteomics revolution. We have developed a large portfolio of antibodies for research use and undertake high throughput polyclonal antibody development projects. Focus areas include neurodegeneration, obesity, asthma and stem cell related proteins. Our antibodies are produced using proven methods using goats kept by hill farmers in Nepal. Purification is by antigen affinity chromatography in our laboratories in Kathmandu. All product design, QC decision making and marketing is based in the UK.
CMP Therapeutics allergic disease therapy
CMP Therapeutics has developed a form of micronised chitin called CMP (chitin microparticles) that has a stimulatory effect on macrophages and dendritic cells and other immune cells in the nasal and respiratory tract. CMP works by mimicking fungal spores, which also contain the carbohydrate chitin and are recognized and removed by immune cells. During this process Th1 cytokines are produced that enhance the innate immune response in the mucosa. This enhances protection against infections such as influenza and additionally counteracts allergic disease including allergic rhinitis (hay fever).
OBI-DSL (UK) Immunoassay sales and development
DSL was established in 1981 with a vision of developing and marketing high quality in vitro diagnostics. This vision, combined with our loyal customers and exclusive dedication to immunodiagnostics, has made DSL a worldwide leader in hormone analysis. By continually exploring new technologies and applications, DSL stays at the forefront of the in vitro diagnostic industry in terms of innovation and responsiveness to evolving laboratory procedures. OBI combines sales representation for DSL with an R&D operation exploiting links with European researchers.
| 
